Staff20192020202120222023
Personnel at the end of the year-----
Staff turnover in EUR525,187562,878566,616620,893664,858
Turnover LabelEUREUREUREUREUR
The share: stated in EUR20192020202120222023
Shares outstanding (in mn.)0.000.000.00189.780.00
Dividend per share-----
Basic earnings per share-----
P/L in EUR million under IAS/IFRS20192020202120222023
Turnover0.00.00.00.00.0
Operating income (EBIT)-87.9-27.7-65.9137.9137.9
Earnings before taxes0.00.00.00.00.0
Annual net profit/ loss0.00.00.00.00.0
Balance sheet in EUR million under IAS/IFRS20192020202120222023
Assets
Total current assets0.00.00.00.00.0
Total fixed assets0.00.00.00.00.0
Total assets0.00.00.00.00.0
Liabilities
Total short-term liabilities0.00.00.00.00.0
Total long-term liabilities0.00.00.00.00.0
Total provisions0.00.00.00.00.0
Equity capital0.00.00.00.00.0
Total liabilities0.00.00.00.00.0
Management:
Richard Meier
Athena Countouriotis
Dennis Slamon
Elaine Heron
May Kin Ho
V. Lawlis
Willard Dere
Barbara Bodem
David Pyott
Elizabeth Anderson
Jean-Jacques Bienaimé
Mark Alles
Mark Enyedy
Robert Hombach
Jean-Jacques Bienaimé
Brinda Balakrishnan
C. Greg Guyer
Amy Wireman
Brian Mueller
G. Eric Davis
Henry J. Fuchs
Jeff Ajer
Philip Lo Scalzo
Board:
Shareholding in %:
Address: 371 Bel Marin Keys Blvd., Suite, CA 94949 Novato
T: (415) 884-6700
F: (415) 382-7889
I: http://www.biomarinpharm.com
E: webmaster@biomarinpharm.com